Cambridge Cognition secures Innovate UK grant

About this update from Cambridge Cognition Holdings Plc

  11 July 2024   Cambridge Cognition Holdings plc (ÒCambridge CognitionÓ, the ÒCompanyÓ or the ÒGroupÓ)   Cambridge Cognition secures Innovate UK grant for Bio-Hermes 2 project   Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to have been selected to provide voice and touchscreen cognitive assessments for the Global AlzheimerÕs Platform FoundationÕs Bio-Hermes 2 project. Cambridge Cognition is receiving grant funding from Innovate UK, the UKÕs innovation agency (as included in the announcement dated 29 May 2024). Three of Cambridge CognitionÕs CANTABª touchscreen cognitive tasks, measuring working memory, episodic memory and processing speed, and a Winterlight speech and language task will be used.   The Bio-Hermes 2 project aims to generate a world-leading dataset to improve the understand ing of how digital and blood-based biomarkers can be used to predict the extent of AlzheimerÕs Disease pathology as detected by positron emission tomography (PET) brain scans .  1,200 patients covering the clinical spectrum of the disease, from normal ageing to mild cognitive impairment and through to dementia, will be monitored for up to 24 months.   With such a sizeable sample of patients over a long period, the project will generate a large dataset that will considerably add to the existing scientific evidence for the CompanyÕs voice and touchscreen assessments . In particular, it will be the first large dataset that the Company will have using both CANTAB and Winterlight assessments, providing an opportunity to have combined assessments for patients in the future to better address emerging needs in AlzheimerÕs Disease drug development.   Matthew Stork, Chief Executive Officer of Cambridge Cognition, commented: "We are delighted that our CANTAB and Winterlight solutions will be in the Bio-Hermes 2 project and are grateful to Innovate UK for the funding. This could be a groundbreaking study for Cambridge Cognition, and indeed for the clinical field, as it could enable the company to be the first to provide a combined all-in-one voice and touchscreen assessment for AlzheimerÕs disease in the futureÕ.     Enquiries:   Cambridge Cognition Holdings plc   Matthew Stork, Chief Executive Officer   Stephen Symonds, Chief Financial Officer   Tel: 012 2381 0700       Panmure Liberum Limited (NOMAD and Joint Broker)   Freddy Crossley / Emma Earl    Rupert Dearden     Tel: 020 7886 2968   (Corporate Finance)   (Corporate Broking)     Dowgate Capital Limited (Joint Broker)   David Poutney / James Serjeant     Tel: 020 3903 7715       Hudson Sandler (Financial PR and IR)   Dan de Belder / Hattie Dreyfus     Tel: 020 7796 4133   [email protected]     Notes to Editors   About Cambridge Cognition   Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.   For further information visit: https://cambridgecognition.com/    

View stock analysis, news, and events for Cambridge Cognition Holdings Plc